Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 20Lymphoma, Follicular 13Waldenstrom Macroglobulinemia 12Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 11Lymphoma, B-Cell 10Leukemia 9Recurrence 8Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphoid 4Leukemia, B-Cell 4Hodgkin Disease 4Bronchiolitis Obliterans Syndrome 4Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Neoplasms 2Lung Neoplasms 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Acute 2Graft vs Host Disease 2Chromosome 17 deletion 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1

Interventions

ruxolitinib 4ponatinib 4nilotinib 4Imatinib Mesylate 411-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2sonidegib 1simtuzumab 1pembrolizumab 1ibrutinib 1bosutinib 1Zoledronic Acid 1Denosumab 1CPI-0610 1BID protein, human 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bone Marrow Diseases × ibrutinib × Clear all
NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
5 enrolled 11 charts
LymphoidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡